Eylea sales growth slowing More From Fool.com He Made 21,078% Buying Amazon. Heres His New Pick Regeneron reported revenue in the third quarter of $1.22 billion, up 7% year over year. http://www.malleyandco.com/truechristiantorres/2016/11/01/tips-for-2015-on-identifying-important-factors-in-eye-surgery/Sales for Eylea made up 70% of total revenue. The good news is that the eye-disease drug saw sales climb 16% compared to the prior-year period, to $854 million. The bad news is that sales growth appears to be slowing. In the second quarter, sales for Eylea were up nearly 27% from the same quarter in 2015. That was slower than the drug’s first-quarter year-over-year sales growth of 44%. Continue Reading Below ADVERTISEMENT Regeneron narrowed its full-year 2016 guidance for Eylea sales. http://lakefeststormlake.com/samanthagomezfun/2016/11/04/no-hassle-strategies-of-astigmatism-clarified/The company now expects 23% to 25% growth over 2015.
For the original version including any supplementary images or video, visit http://www.foxbusiness.com/markets/2016/11/04/3-things-really-need-to-know-about-regeneron-pharmaceuticals-q3-results.html